Focused On-demand Library for Small vasohibin-binding protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8N300

UPID:

SVBP_HUMAN

Alternative names:

Coiled coil domain-containing protein 23

Alternative UPACC:

Q8N300; A8K5P1; D3DPW7

Background:

The Small vasohibin-binding protein, also known as Coiled coil domain-containing protein 23, plays a pivotal role in cellular processes. It enhances the tyrosine carboxypeptidase activity of VASH1 and VASH2, crucial for the removal of the C-terminal tyrosine residue of alpha-tubulin. This action is vital for spindle function and accurate chromosome segregation during mitosis, regulating mitotic spindle length and positioning. Additionally, it supports axon and excitatory synapse formation, and enhances the solubility and secretion of VASH1 and VASH2.

Therapeutic significance:

Linked to a neurodevelopmental disorder characterized by intellectual disability, microcephaly, ataxia, and muscular hypotonia, the Small vasohibin-binding protein's role in disease underscores its potential as a target for therapeutic intervention. Understanding its function could pave the way for novel treatments for related neurodevelopmental disorders.